
About Ksilink & key figures
Ksilink is bundling academic and industrial forces to address diseases where no other therapeutic approaches have proven effective or ever existed.
Our Business Model
We create a pipeline of patient-based drug discovery programs in muscular and neurologic disorders, as well as oncology. We develop them as collaborative proprietary programs in an open innovation model up to lead compounds.
Our Differentiating Features
Leaning on the power of AI-driven image analysis, we use the full potential of our complex patient-based disease models for drug discovery. Our efforts are strengthen and accelerated by aligning outstanding expertise in an end-to end approach, from early disease modelling up to first-in-class compounds.
Our Why
Discovering new drugs solving today’s unmet medical needs.
Advancing science by making outstanding expertise available and reliable for the pharmaceutical industry.
Achieving great outcomes faster by building precision networks in an integrated end-to-end approach.